8 4 chlorophenylthio adenosine 3 5 cyclic monophosphate 8 cpt camp

8-(4-chlorophenylthio) adenosine-3’,5’-cyclic monophosphate (8-CPT-cAMP) was purchased from BIOLOG Life Science Institute. The inhibitors 9-(tetrahydro-2-furanyl)-9H-purin-6-amine (SQ22536), 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126), N-[2-[[3-(4-bromophenyl)-2-propenyl-]amino]ethyl]-5-isoquinolinesulfonamide dihydrochloride (H-89), and α-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile (SL327), and D1 receptor ligands SKF81297 hydrobromide and SCH-23390 hydrochloride were purchased from Tocris. Reserpine and phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma. Drug stocks were prepared at 50 or 100 mM in DMSO, followed by dilution in culture media to final concentrations of 100 μM 8-CPT-cAMP, 10 μM Reserpine, 10 μM U0126, 30 µM H89, 1 mM SQ22536, 10 µM SCH-23390, 10 µM SKF 81297, and 100 nM PMA.

Forskolin (FSK), H-89 dihydrocloride (H89), Calyculin A (CalA), 3-isobutyl-1-methylxantine (IBMX), Chloroquine (ChQ), dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), Tween 20, bovine serum albumin (BSA), and skim milk powder were from Merck KGaA (Darmstadt, Germany). 8-(4-Chlorophenylthio) adenosine-3′, 5′- cyclic monophosphate (8CPT-cAMP) was from BioLog (BioLog Life Science Institute GmbH & Co. KG, Bremen, Germany).